Clinical Studies

Year Number of Subjects Title of Publication Summary Publication Link
2016 584 Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury GFAP performed consistently in detecting MMTBI, CT lesions, and neurosurgical intervention across 7 days.  UCH-L1 performed best in the early postinjury period. JAMA Neurology View Resource
2015 251 Ability of Serum Glial Fibrillary Protein, Ubiquitin C-Terminal Hydrolase_L1, and S100B to Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury The results demonstrated 100% sensitivity and 39% specificity with UCH-L1 at 6 hours after a TBI. Journal of Neurotrauma View Resource
2014 206 Acute Biomarkers of Traumatic Brain Injury: Relationship between Plasma Levels of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein (TRACK-TBI) The results demonstrate a role for multiple biomarker measurements in TBI research. Journal of Neurotrauma View Resource
2013 215 GFAP-BDP as an Acute Diagnostic Marker in Traumatic Brain Injury: Results from the Prospective Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study (TRACK-TBI) The results demonstrate that measurement of serum GFAP-BDP may improve the ability of clinicians to identify TBI patients who may require further medical evaluation and management. Use of GFAP-BDP as a serum biomarker for TBI should lead to more accurate diagnosis and management of TBI. Journal of Neurotrauma View Resource
2012 95 Clinical utility of serum levels of ubiquitin c-terminal hydrolase as a biomarker for severe traumatic brain injury Serum levels of UCH-L1 appear to have potential clinical utility in diagnosing TBI, including correlating to injury severity and survival outcome Neurosurgery View Resource
2012 45 Brain injury biomarkers may improve the predictive power of the IMPACT Outcome Calculator Results underline the importance of biomarkers in outcome prediction, and encourage further investigation to expand the predictive power of contemporary outcome calculators and prognostic models in TBI Journal of Neurotrauma View Resource
2012 307 Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention GFAP-BDP is detectable in serum within an hour of injury and is associated with measures of injury severity, including the GCS score, CT lesions, and neurosurgical intervention Annals of Emergency Medicine View Resource
2012 295 Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in
mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention
UCH-L1 is detectable in serum within an hour of injury and is associated with measures of injury severity including the GCS score, CT lesions, and NSI Journal of Trauma View Resource
2011 248 Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study Protein biomarker could provide better characterization of subjects at risk for specific types of cellular damage than that obtained with neuroimaging alone, as well as provide valuable information about injury severity and outcome after severe TBI Critical Care Medicine View Resource
2010 66 Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury UCH-L1 protein is present in human CSF and that its levels were significantly elevated after severe TBI using enzyme-linked immunosorbent assay (ELISA) analysis. UCH-L1 was detectable in CSF very early after injury and was associated with measures of injury severity and outcome Critical Care Medicine View Resource